As a first approach to examining the biological significance of elevated YB-1 expression on the in vivo tumorigenic properties of human breast cancer cells with altered KRAS or AKT expression, we focused on determining the effect of reducing YB-1 protein levels in MDA-MB-231 cells. This evidence concerns the gene KRAS and breast carcinoma.